Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer

Abstract

Background Roles of cancer stem cells and early growth response gene 1 (Egr1) in carcinogenesis have been extensively studied in lung cancer. However, the role of Egr1 in the metastasis of lung cancer remains undetermined, especially in regard to stem cell-related pathways. Methods Egr1, osteopontin (OPN) and Oct4 expression in human lung cancer was determined by performing immunohistochemistry. Immunoblotting, ELISA, luciferase reporter assay, chromatin immunoprecipitation assay and RT-PCR were performed to validate the regulation of Oct4-Egr1-OPN axis. Moreover, the effect of Oct4-Egr1-OPN axis on lung cancer progression was evaluated by cell migration assay and mice study. Results We detected Oct4, Egr1, and OPN expression in clinical specimens from 79 lung cancer patients, including 72 adenocarcinomas and 7 squamous cell carcinomas. High expression of Oct4, Egr1, and OPN accounted for 53, 51, and 57% of the patients, respectively. All of the three biomarkers were positively correlated in clinical human lung cancer. Patients with high expression of OPN were significantly associated with shorter disease-free survivals than those with low expression of OPN ( p < 0.05). In lung cancer cells, Oct4 transactivated the Egr1 promoter and upregulated Egr1 expression. In a human lung cancer xenograft model, Oct4-overexpressing tumors expressed elevated levels of Egr1. Furthermore, overexpression of Oct4 in lung cancer cells increased the metastatic potential. Conclusions Egr1 exerts a promoting effect on cancer metastasis in Oct4-overexpressing lung cancer. Thus, therapeutic strategies targeting the Oct4/Egr1/OPN axis may be further explored for the treatment of lung cancer, especially when lung cancer is refractory to conventional treatment due to cancer stem cells. Electronic supplementary material The online version of this article (10.1186/s12885-019-6014-5) contains supplementary material, which is available to authorized users.

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation

“…As such, it is emerging as an important cancer biomarker and its relevance in PI3K/Akt and integrin-NF-κB/HIF-1α pathways is currently a focus of ongoing research [ 93 , 94 , 95 , 96 , 97 , 98 ]. OPN expression in the context of cancer includes regulation by hyaluronic acid, IL-6, transmembrane protein TM4SF4, and Oct4-Egr1 pathway [ 94 , 99 , 100 , 101 ]. Angiogenesis, degradation of ECM, the formation of lamellipodia, and switching phenotypes towards either cancer-associated fibroblasts or stem cells are ways in which OPN can promote invasion and metastasis.…”

The Matrix Revolution: Matricellular Proteins and Restructuring of the Cancer Microenvironment

“…SPARC has been suggested as a prognostic biomarker for certain cancers such as soft tissue sarcoma, esophageal SCC and glioblastoma since its expression correlates with poor survival (232)(233)(234). In addition, SPP1 may be prognostic for breast, lung, gastric, liver and colon cancers since it associated with tumor progression and decreased patient survival (235)(236)(237)(238).…”

Osteopontin as a Novel Biomarker for the Prognosis and Clinical Pathology of Prostate Cancer: A Systematic Review and Meta-Analysis

“…Lindahl's [36] study has shown that OPN can serve as an in ammatory mediator to the pathogenesis of breast cancer. Feng's [37] study shows that the upregulation of OPN is not conducive to the survival in human lung cancers. However, our study is the rst meta-analysis to discuss the relationship between survival and OPN expression, and we also evaluate the expression of OPN in different prostate tissues and different clinical parameters.…”